Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors (clinicaltrials.gov) - Sep 23, 2026 - P1 | N=33 | Suspended | Sponsor: Washington University School of Medicine | Recruiting ➔ Suspended
Checkpoint inhibition • Trial suspension • Melanoma • Oncology • Solid Tumor • PD-L1
|